Revolutionizing Liquid Nitrogen Delivery in Biopharmaceuticals

07 December 2024

By: Howard Chan

The Role of CSM's Cryogenic Vacuum Insulated Pipe and Phase Separator

In the biopharmaceutical industry, the pursuit of innovation extends beyond product development to optimizing processes for sustainability and efficiency. With growing emphasis on reducing environmental impact and achieving a lower carbon footprint, liquid nitrogen (LN2) systems have become a critical focus. 

Superior Technology for Optimal Performance

At the heart of CSM's VIP and Phase Separator is high-performance super insulation technology, which minimizes thermal conductivity.

  • The vacuum insulation acts as a barrier to heat transfer, ensuring that liquid nitrogen remains at its desired cryogenic temperature during transportation and distribution.
  • This innovation not only preserves the efficiency of LN2 systems but also reduces the LN2 losses associated with thermal conductivity, directly contributing to a reduced carbon footprint in system operation.

Let’s explore how this technology drives sustainability and operational excellence in key biopharmaceutical applications:

1. Lyophilization with LN2

Lyophilization, or freeze-drying, is a critical process for preserving biological materials, including proteins, vaccines, and pharmaceutical compounds. The precise maintenance of low temperatures during lyophilization is essential to ensure product quality and stability. Cryogenic lyophilization is particularly valuable for biopharmaceutical applications where maintaining product quality and stability is paramount. By leveraging advanced technologies like CSM's vacuum-insulated liquid nitrogen delivery systems, the efficiency and sustainability of this critical process are further enhanced.

Working Principle of Cryogenic Lyophilization

Cryogenic lyophilization, also known as freeze-drying, is a process used to preserve sensitive biological and     pharmaceutical materials by removing water through sublimation under low-temperature and low-pressure conditions. This method relies on the use of cryogenic cooling, often facilitated by liquid nitrogen (LN2), to achieve the ultra-low temperatures required for the process.

Key Steps in Cryogenic Lyophilization

      A. Freezing

  • The product is frozen to convert the water content into solid ice.
  • Cryogenic systems using LN2 rapidly cool the material to temperatures typically below −50∘C.
  • LN2 ensures uniform and precise temperature control, critical for preserving the structural and chemical integrity of sensitive products.

      B. Primary Drying (Sublimation)

  • Under reduced pressure (vacuum), heat is gently supplied to the frozen material, causing the ice to directly convert into vapor without passing through a liquid phase (sublimation).
  • LN2-cooled systems maintain a consistent low temperature to prevent the product from melting or collapsing.

      C. Secondary Drying (Desorption)

  • Residual moisture is removed by increasing the temperature slightly while maintaining a vacuum.
  • LN2 systems maintain a controlled temperature gradient, ensuring the product remains stable during this phase.

Role of Cryogenic Cooling in Lyophilization

  • Rapid Cooling: LN2 enables quick freezing, reducing the formation of large ice crystals that could damage the product’s cellular structure.
  • Precise Temperature Control: Cryogenic systems provide consistent and uniform cooling, ensuring even drying across the product batch.
  • Energy Efficiency: LN2 cooling systems can achieve ultra-low temperatures efficiently, reducing the energy required compared to conventional refrigeration methods.

Advantages of Cryogenic Lyophilization

  • Product Integrity: Maintains the structural and biochemical stability of sensitive materials like biologics, vaccines, and pharmaceuticals.
  • Scalability: Suitable for small-scale research applications and large-scale industrial production.
  • Faster Process: Cryogenic cooling accelerates the freezing phase, optimizing overall lyophilization time.
  • Sustainability: Efficient LN2 systems reduce energy consumption and environmental impact.

CSM Solution: The highly efficient VIP system minimizes heat ingress, ensuring the LN2 supplied to lyophilizers remains consistently cold. The Phase Separator further enhances performance by maintaining uniform LN2 delivery, eliminating temperature fluctuations.

Sustainability Impact: Reduced LN2 consumption translates to lower operational costs and a greener process. By optimizing LN2 usage, the system supports energy-efficient lyophilization with minimal waste.

2. Blast Freezing with LN2

Blast freezing is widely used for the rapid preservation of biological products for pharmaceuticals application. Maintaining ultra-low temperatures during this process is critical to preventing degradation and ensuring quality.

Working Principle of Blast Freezing

Blast freezing is a rapid cooling process used to preserve the quality and extend the shelf life of biological products, temperature-sensitive drugs and compounds. It works by exposing products to extremely low temperatures (−30∘C to −50∘C or lower) using high-velocity cold air with cryogenic cooling agents like liquid nitrogen (LN2). The primary goal is to quickly lower the temperature of the product to prevent the formation of large ice crystals, which can damage cellular structures and compromise quality.

Key Steps in Blast Freezing

      A. Preparation of the Product

  • The product is pre-cooled or brought to ambient temperature before blast freezing begins.
  • Items are arranged to allow for maximum exposure to cold air or cryogenic gas during freezing.

      B. Rapid Freezing

  • The product is exposed to:
    • High-Velocity Cold Air: Mechanical systems circulate air at high speeds over the product to enhance heat transfer.
    • Cryogenic Cooling: LN2 is used to rapidly cool the product.
  • The freezing process occurs within minutes to hours, depending on the product size and freezing system.

      C. Temperature Reduction

  • The product's core temperature is quickly reduced to below its freezing point (typically −18∘C or lower).
  • LN2 systems ensure uniform temperature distribution and ultra-low temperatures in a controlled environment.

       D. Storage

  • Once the product reaches the desired temperature, it is transferred to a storage facility where the temperature is maintained to preserve quality.

Principle of Ice Crystal Formation

  • Slow Freezing: Leads to the formation of large ice crystals, which can damage the cellular or molecular structure of products, causing quality degradation.
  • Blast Freezing: Rapidly reduces the temperature, forming small ice crystals that preserve integrity, and quality.

Role of Liquid Nitrogen (LN2) in Blast Freezing

  • Ultra-Low Temperatures: LN2 can achieve temperatures as low as −196∘C, enabling faster freezing than traditional mechanical systems.
  • High Efficiency: LN2 vapor is evenly distributed across the product surface, ensuring uniform freezing.
  • Minimized Oxidation and Moisture Loss: Cryogenic freezing reduces dehydration and oxidation, maintaining product quality.

Advantages of Blast Freezing

  • Rapid Process: Reduces freezing time, maintaining product quality and minimizing degradation.
  • Preservation of Texture and Quality: Small ice crystals prevent damage to cellular structures.
  • Energy Efficiency: Cryogenic systems, like those using LN2, optimize energy use by delivering instant cooling.
  • Versatility: Suitable for a wide range of products, including biologics, food, and pharmaceuticals.

CSM Solution: The advanced insulation in VIP systems reduces heat ingress along the LN2 pipeline, enabling faster and more efficient freezing. The Phase Separator ensures consistent LN2 supply, avoiding pressure drops and temperature inconsistencies.

Sustainability Impact: Improved efficiency means less LN2 is required for each freezing cycle, reducing operational costs and environmental impact. Faster freezing times also optimize energy use in LN2 production and storage.

3. Low-Temp. Storage for Biologics & Cells

The storage of biologics and cells at ultra-low temperatures is indispensable for research and clinical applications. Cryogenic storage systems depend on the reliable supply of LN2 to maintain critical temperatures.

Working Principle of Cryogenic Cell Preservation

Cryogenic cell preservation, also known as cryopreservation, is the process of preserving cells, tissues, or other biological samples at ultra-low temperatures to halt all biological activity and biochemical reactions. The goal is to maintain the integrity, viability, and functionality of cells for extended periods. This process is commonly achieved using liquid nitrogen (LN2), which provides the ultra-low temperatures necessary for long-term storage.

Key Steps in Cryogenic Cell Preservation

       A. Preparation of Samples

  • Cell Viability Testing: Only viable and healthy cells are selected for preservation.
  • Cryoprotectant Addition: Cryoprotective agents (CPAs), such as dimethyl sulfoxide (DMSO) or glycerol, are added to prevent ice crystal formation, which can damage cell membranes.   

      B. Controlled Freezing

  • Slow Cooling: The cells are gradually cooled to a critical temperature (usually −80∘C-80^\circ C−80∘C) using a controlled-rate freezer. This slow cooling minimizes ice crystal formation inside the cells.
  • Vitrification: In some cases, cells are rapidly cooled to achieve a glass-like solid state without forming ice crystals.

      C. Cryogenic Storage

  • After initial freezing, samples are transferred to a cryogenic storage system.
  • Liquid Nitrogen Storage: The samples are stored in vapor-phase or liquid-phase LN2, typically at temperatures below −150∘C-150^\circ C−150∘C. At these temperatures, biological activity and chemical reactions are completely halted.

      D. Thawing and Recovery

  • When needed, the samples are rapidly thawed at a controlled rate to minimize ice recrystallization.
  • The cryoprotectant is carefully removed to avoid toxicity, and the cells are restored to a viable state for use.

CSM Solution: The robust design of VIP and Phase Separator systems ensures uninterrupted LN2 supply to cryogenic storage units. The technology minimizes boil-off, extending the duration between LN2 refills and reducing the risk of temperature fluctuations.

Sustainability Impact: Lower LN2 consumption leads to significant reductions in operational energy usage and carbon emissions, aligning with the industry's sustainability goals.

Why Choose CSM?

  • 10-Year Vacuum Insulation Warranty: Demonstrates our commitment to durability and performance.
  • Proven Expertise: Decades of experience in cryogenic systems tailored to high-demand industries.
  • Sustainability Focus: Products designed to optimize LN2 usage, reduce energy consumption, and lower carbon footprints.
  • Comprehensive Support: From system design to installation and maintenance, CSM delivers end-to-end solutions for biopharmaceutical applications.

A Greener Future for Biopharma Processes

As biopharmaceutical companies strive for innovation and sustainability, solutions like CSM's Cryogenic VIP and Phase Separator are paving the way for greener, more efficient processes. By significantly reducing heat loss and optimizing LN2 delivery, these systems empower industries to meet both performance and environmental objectives.

For more information on how CSM can transform your cryogenic systems, visit www.csm-cryogenic.com.

   Back

Latest Blog

Blog Categories